MoonLake Immunotherapeutics submitted a Biologics License Application (BLA) to the FDA for sonelokimab to treat moderate-to-severe hidradenitis suppurativa, aiming for U.S. approval. The company reported positive Phase 3 trial results for psoriatic arthritis, meeting all clinical endpoints, and completed enrollment for a second Phase 3 trial with topline results expected in early 2027. MoonLake also plans to start a Phase 3 trial for palmoplantar pustulosis in November 2026. Financially, MoonLake ended Q3 2026 with $498.5 million in cash and expects funding through mid-2028, supported by an additional $400 million debt facility. These developments position MoonLake for a potential U.S. commercial launch of sonelokimab in 2027, pending regulatory approval.
MoonLake Immunotherapeutics' Q3 2026 financial results and business update provide context for readers. For those following the health sector, 118 of 150 priced US health stocks on Pluang rose while 24 fell. Notable movers as of Nov 04, 2026 18:41 WIB include THC at USD 279.75 with a 4.90% increase and 100% sell order activity, CNC at USD 70.40 up 4.33%, and ABEO at USD 4.41 rising 3.76% with 100% buy order activity.
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
Dimensional Fund Advisors Ltd. has disclosed an interest in 1,516,595 ordinary shares of DCC Energy plc, representing 1.78% of the company's shares as of November 3, 2026. The disclosure follows regulatory requirements under the Irish Takeover Panel ...
AMD reported record revenue growth in 2026, reaching $13.37 billion in Q3, but its free cash flow margin sharply dropped to about 4%. The company increased inventory significantly to meet strong data center demand, causing cash tied up in unsold good...
